ifa systems Valuation

Is IS8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IS8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IS8's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IS8's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IS8?

Key metric: As IS8 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for IS8. This is calculated by dividing IS8's market cap by their current book value.
What is IS8's PB Ratio?
PB Ratio	n/a
Book	€9.41m
Market Cap	€6.05m

IS8 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does IS8's PB Ratio compare to its peers?

The above table shows the PB ratio for IS8 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	2.1x
AJ91 DocCheck	1.1x	n/a	€41.4m
M3V MeVis Medical Solutions	2.6x	n/a	€45.1m
UOM AS Latvijas Juras medicinas centrs	0.9x	n/a	€5.4m
AUG Audientes	3.9x	n/a	€6.9m
IS8 ifa systems	n/a	n/a	€6.1m

Price-To-Book vs Peers: Insufficient data to calculate IS8's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Book Ratio vs Industry

How does IS8's PB Ratio compare vs other companies in the European Healthcare Services Industry?

6 Companies	Price / Book	Estimated Growth	Market Cap

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: Insufficient data to calculate IS8's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is IS8's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IS8 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	n/a
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IS8's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

4A5

€18.18

-2.7%

6.1%

Shandong Weigao Group Medical Polymer

HK$20.7b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.54

-1.8%

-37.1%

LNA Santé

€242.3m

Engages in the management and operation of health establishments.

2N3

€23.25

-6.8%

15.7%